Role of thalidomide in previously untreated patients with multiple myeloma

Pellegrino Musto, Fiorella D'Auria, Giuseppe Pietrantuono, Sara Bringhen, Fortunato Morabito, Francesco Di Raimondo, Samantha Pozzi, Stefano Sacchi, Mario Boccadoro, Antonio Palumbo

Research output: Contribution to journalArticlepeer-review


Thalidomide represents one of the most relevant therapeutic advances for patients with multiple myeloma over the last 10 years. Despite some toxicities, it has demonstrated significant efficacy in elderly patients, as well as in the setting of younger subjects receiving autologous stem cell transplantation. Here, we report and discuss the clinical results achieved with thalidomide alone or in combination with dexamethasone or other drugs, such as melphalan, cyclophosphamide, doxorubicin and bortezomib, in previously untreated myeloma patients.

Original languageEnglish
Pages (from-to)1569-1580
Number of pages12
JournalExpert Review of Anticancer Therapy
Issue number10
Publication statusPublished - 2008


  • Bortezomib
  • Cyclophosphamide
  • Dexamethasone
  • Doxorubicin
  • First-line therapy
  • Lenalidomide
  • Melphalan
  • Myeloma
  • Peripheral neuropathy
  • Thalidomide
  • Thrombosis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology


Dive into the research topics of 'Role of thalidomide in previously untreated patients with multiple myeloma'. Together they form a unique fingerprint.

Cite this